The approval of ES 2486441 and ES2486442 patents is a recognition in terms of research and innovation behind Lit-Control pH Up® and Lit-Control pH Down® products, and allow Devicare to protect its products and exploit them exclusively on throughout the national territory.

Both formulations are based on combined preparations of urinary basifiers or acidifiers and crystallization inhibitors for the treatment or prevention of renal lithiasis induced by uric acid or calcium phosphate respectively.

Renal lithiasis induced by uric acid tends to form uric acid, calcium oxalate, or mixed stones of uric acid with calcium oxalate. Therefore, the Lit-Control pH Up® nutritional supplement, helps increasing urinary pH, in order to keep it in a preventive range for the formation of kidney stones. While renal lithiasis induced by calcium phosphate, tends to form hydroxyapatite, brushite, calcium oxalate, or mixed stones of calcium phosphate and calcium oxalate. Thus, the Lit-Control pH Down® nutritional supplement, helps decreasing the urinary pH, in order to keep it in a preventive range for the formation of kidney stones.

Renal lithiasis affects more than 325,000 people each year and an estimated 80% of them end up forming another kidney stone, adding to the more than 2,200,000 cases of kidney stones in Spain according to Puigvert’s Foundation studies.

bodegon_productos_LitControl